These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Rituximab therapy for Morvan syndrome associated with myasthenia gravis. Weiss M Muscle Nerve; 2012 Jul; 46(1):139-40. PubMed ID: 22693003 [No Abstract] [Full Text] [Related]
4. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. Stein B; Bird SJ J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497 [No Abstract] [Full Text] [Related]
5. Use and monitoring of low dose rituximab in myasthenia gravis. Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753 [TBL] [Abstract][Full Text] [Related]
6. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis. Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503 [No Abstract] [Full Text] [Related]
13. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Sun F; Ladha SS; Yang L; Liu Q; Shi SX; Su N; Bomprezzi R; Shi FD Muscle Nerve; 2014 Apr; 49(4):487-94. PubMed ID: 23868194 [TBL] [Abstract][Full Text] [Related]
14. Concurrent diffuse alveolar haemorrhage and venous thromboembolism in p-ANCA associated vasculitis treated with rituximab. Yun S; Howe LN; Afshar S; Jahan K BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24916986 [No Abstract] [Full Text] [Related]
15. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772 [No Abstract] [Full Text] [Related]
16. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. Sadnicka A; Reilly MM; Mummery C; Brandner S; Hirsch N; Lunn MP J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):230-2. PubMed ID: 20462915 [TBL] [Abstract][Full Text] [Related]
17. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study. Singh N; Goyal V J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039 [TBL] [Abstract][Full Text] [Related]
18. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Marie I; Dominique S; Janvresse A; Levesque H; Menard JF Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877 [TBL] [Abstract][Full Text] [Related]
19. Rituximab in the management of refractory myasthenia gravis. Zebardast N; Patwa HS; Novella SP; Goldstein JM Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027 [TBL] [Abstract][Full Text] [Related]
20. Rituximab for myasthenia gravis: three case reports and review of the literature. Stieglbauer K; Topakian R; Schäffer V; Aichner FT J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]